



Pediatric COVID-19 Vaccine Information (Children 6 Months Through 4 Years of Age)

6 Months Through 4 Years of Age Updated (2023–2024 Formula) Pfizer-BioNTech COVID-19 Vaccine for those who are NOT moderately or severely immunocompromised*

COVID-19 vaccination history [†] (regardless of COVID-19 vaccine formula)	Schedule for administration of 2023-24 Pfizer-BioNTech COVID-19 Vaccine
Unvaccinated	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> ▪ Dose 1 now ▪ Dose 2 at least 3–8 weeks after Dose 1[‡] ▪ Dose 3 at least 8 weeks after Dose 2
1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [§]	Complete series. Administer: <ul style="list-style-type: none"> ▪ Dose 2 at least 3–8 weeks after Dose 1[‡] ▪ Dose 3 at least 8 weeks after Dose 2
2 doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) ^{§¶}	Complete series. Administer: <ul style="list-style-type: none"> ▪ Dose 3 at least 8 weeks after Dose 2
3 or more doses Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [§]	Give 1 dose at least 8 weeks (2 months) after the previous dose.
3 or more doses Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [§]	No further doses are indicated.

* Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.

‡ An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

§ People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

¶ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose.

6 Months Through 4 Years of Age Updated (2023–2024 Formula) Pfizer-BioNTech COVID-19 Vaccine for those who ARE moderately or severely immunocompromised*

COVID-19 vaccination history* (regardless of COVID-19 vaccine formula)	Schedule for administration of 2023-24 Pfizer-BioNTech COVID-19 Vaccine
Unvaccinated	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> ▪ Dose 1 now ▪ Dose 2 at least 3 weeks after Dose 1 ▪ Dose 3 at least 8 weeks after Dose 2
1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1)†	Complete series. Administer: <ul style="list-style-type: none"> ▪ Dose 2 at least 3 weeks after Dose 1 ▪ Dose 3 at least 8 weeks after Dose 2
2 doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2)†‡	Complete series. Administer: <ul style="list-style-type: none"> ▪ Dose 3 at least 8 weeks after Dose 2
3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine†	Give 1 dose at least 8 weeks (2 months) after the previous dose.
3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine †	<ul style="list-style-type: none"> ▪ People who are moderately or severely immunocompromised have the option to receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose. ▪ Further additional dose(s) may be administered, informed by the clinical judgement of a health care provider and personal preference and circumstances. ▪ Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose.

* COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

‡ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose.